Issue: Volume XXII, Number 18 - December 28, 2015

This category can only be viewed by members.

Lab Industry’s Non-Stories for 2015

AT THE END OF EACH YEAR, IT IS GENERALLY EASY TO PICK OUT the stories of greatest significance for the lab industry during the previous 12 months. But what is often overlooked are the non-stories. These are the events that did not happen in the year, despite earlier occurrences and the momentum pushing certain trends …

Lab Industry’s Non-Stories for 2015 Read More »

This post is only available to members.

2015’s Top 10 Lab Stories Show Significant Changes

CEO SUMMARY: During 2015, two stories captured the full attention of most pathologists and clinical lab managers. One was how CMS intends to gather lab price market data as mandated by PAMA. The other was the continued efforts by the FDA to move ahead on proposed guidance for regulation of LDTs. However, the full list …

2015’s Top 10 Lab Stories Show Significant Changes Read More »

This post is only available to members.

Labs Can Earn Revenue through Data Analytics

CEO SUMMARY: There is a new buyer for lab test data, creating an opportunity for labs to build a new revenue stream. Medivo, Inc., of New York, describes itself as a healthcare data analytics company whose mission is to unlock the power of lab data to improve health. It works with clinical labs and pathology …

Labs Can Earn Revenue through Data Analytics Read More »

This post is only available to members.

Letter from Congress to CMS Asks for Delay in PAMA Reporting

CLINICAL LABORATORY ASSOCIATIONS are using a letter-writing campaign to members of Congress as a last-minute Hail Mary attempt to head off the controversial lab price market reporting rule that CMS intends to implement after January 1. Both Democrats and Republicans in the U.S. House of Representatives and the U.S. Senate have signed a letter to …

Letter from Congress to CMS Asks for Delay in PAMA Reporting Read More »

This post is only available to members.

FDA Official Makes Case In Favor of LDT Guidance

CEO SUMMARY: Forty years ago, pathologists in hospital and academic labs worked closely with treating physicians to produce laboratory-developed tests for discrete clinical cases. Seeing that, the FDA decided not to regulate those tests, an FDA official said. Over time, however, use of LDTs became a serious concern when labs developing LDTs were no longer involved …

FDA Official Makes Case In Favor of LDT Guidance Read More »

This post is only available to members.

December 28, 2015 Intelligence: Late Breaking Lab News

To advance the practice of precision medicine through better use of genetic testing, a new limited liability corporation (LLC) was formed. Participating in the LLC are North Shore-LIJ Health System, the nation’s largest urban health system, OPKO Health, Inc., a pharmaceutical company, and GeneDx, a division of Bio-Reference Laboratories (both lab businesses are owned by OPKO). …

December 28, 2015 Intelligence: Late Breaking Lab News Read More »

This post is only available to members.

;